Amunix is an immuno-oncology company leveraging Pro-XTEN technology platform to discover and develop transformative therapies for patients with cancer.
Total raised: $190M
Investors 5
| Date | Name | Website |
| - | Spur Capit... | spurcapita... |
| - | Omega Fund... | omegafunds... |
| - | Frazier Li... | frazierls.... |
| - | Longitude ... | longitudec... |
| - | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.03.2021 | Series B | $117M | BlackRock |
| 05.03.2020 | Series A | $73M | - |
Mentions in press and media 20
| Date | Title | Description |
| 01.08.2025 | Frazier Life Sciences: $1.3 Billion Venture Fund Closed | Frazier Life Sciences (FLS), an investment firm focused on innovative therapeutics, announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong s... |
| 22.07.2025 | Omega Funds: $647 Million Fund VIII Closed To Invest In Life Science Companies | Global healthcare venture capital firm Omega Funds has closed its eighth fund at $647 million, surpassing its initial target of $600 million. The oversubscribed Omega Fund VIII, L.P., received backing from both new and existing investors. I... |
| 20.12.2021 | Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics | Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics Adds promising pipeline of T-cell engagers and cytokine therapies with lead candidate AMX-818 expected to enter the clinic in early 202... |
| 08.03.2021 | Amunix Raises $117M in Series B Financing | Amunix Pharmaceuticals, Inc., a South San Francisco, CA-based biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumo... |
| 05.03.2021 | Amunix secures $117M Series B | Biopharma startup Amunix has raised $117 million in a Series B led by Viking Global, with support from Bain Capital Life Sciences, BlackRock, Avidity Capital, Omega Funds, ArrowMark Partners and others. The South San Francisco-based company... |
| 04.03.2021 | With $117M in fresh cash, Amunix paves path to the clinic for 'universal mask' prodrug on the hunt for HER2 tumors | Despite all the excitement over the possibility of T cell therapies to crack the code against solid tumors, early safety data have limited the burgeoning field’s promise. A clutch of players hope to solve that problem by... |
| 04.03.2021 | Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline | Proceeds will fund advancement of the company’s pipeline of protease-activated T cell engagers and cytokines for the treatment of solid tumorsFunding round supported by top-tier crossover investor syndicate, including Viking Global Investor... |
| 04.03.2021 | Amunix scores $117M to fuel T-cell engagers, cytokines for solid tumors The BD&L Summit has gone virtual! | Exactly one year after Amunix Pharmaceuticals raised $73 million, the tech-licensing company turned cancer biotech is drawing another $117 million from the venture capital well. The funds will fuel the development of T-cell engager and cyto... |
| 04.03.2021 | Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline | Proceeds will fund advancement of the company’s pipeline of protease-activated T cell engagers and cytokines for the treatment of solid tumorsFunding round supported by top-tier crossover investor syndicate, including Viking Global Investor... |
| 04.03.2021 | Amunix scores $117M to fuel T-cell engagers, cytokines for solid tumors | Exactly one year after Amunix Pharmaceuticals raised $73 million, the tech-licensing company turned cancer biotech is drawing another $117 million from the venture capital well. The funds will fuel the development of T-cell engager and cyto... |
Show more